The P-I/II (STARMAP) study assesses BBI 825’s safety, PK, PD biomarkers, preliminary antitumor activity, MTD & RP2D as monotx. & in combination with select targeted therapies
The part 1 evaluates BBI-825 alone to treat solid tumors, part 2 evaluates BBI 825 combined with encorafenib & cetuximab or adagrasib & cetuximab to treat advanced/metastatic, BRAFV600E or KRASG12C mutated colorectal cancer, respectively & co-occurring resistance gene amplifications while part 3 evaluates anti-tumor activity of the determined RP2D
BBI-825 is a small molecule that inhibited low double digit nanomolar RNR & tumor growth to prevent & treat amplification-mediated resistance in MAPK pathway-activated tumors in its preclinical study
Ref: Boundless Bio | Image: Boundless Bio
Related News:- Boundless Bio Entered into a Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate Lytgobi + BBI-355 for FGFR Amplified Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
